Research Topics
Genomes and Genes | T B DruekeSummaryCountry: France Publications
| Collaborators
|
Detail Information
Publications
Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overviewGlenn M Chertow
Department of Medicine, University of California at San Francisco, San Francisco, California, USA
Clin J Am Soc Nephrol 2:898-905. 2007..However, no prospective trials have evaluated whether interventions that modify these laboratory parameters result in a reduction in adverse cardiovascular outcomes...- Dietary salt restriction accelerates atherosclerosis in apolipoprotein E-deficient miceOgnen Ivanovski
INSERM Unit 507, Necker Hospital, 161 rue de Sevres, 75015 Paris, France
Atherosclerosis 180:271-6. 2005..The present study was designed to investigate the effects of low dietary salt on atherosclerotic lesion progression in apolipoprotein E deficient (apoE(-/-)) mice... - Intestinal absorption of aluminium in renal failureTilman B Drueke
INSERM Unit 507, Hopital Necker, 161 rue de Sevres, F 75743 Paris Cedex 15, France
Nephrol Dial Transplant 17:13-6. 2002.... - Advanced oxidation protein products, parathyroid hormone and vascular calcification in uremiaTilman B Drueke
Inserm U507 et Service de Néphrologie, Hopital Necker, Paris, France
Blood Purif 20:494-7. 2002..These latter risk factors may even have a better predictive value than classical risk factors for coronary heart disease in uremic patients... - Treatment of secondary hyperparathyroidism with vitamin D derivatives and calcimimetics before and after start of dialysisTilman B Drueke
Inserm Unit 507 et Service de Néphrologie, Hopital Necker, Paris, France
Nephrol Dial Transplant 17:20-2. 2002..Here, we focus on recent advances in the prevention and treatment of secondary hyperparathyroidism by vitamin D derivatives and by calcimimetic agents... - Stopping a medical research project for financial reasonsTilman B Drueke
, , , 75743 Paris Cedex 15, France
Nephrol Dial Transplant 18:1982-3. 2003 - Calcimimetics versus vitamin D: what are their relative roles?Tilman B Drueke
Inserm Unit 507 and Service de Néphrologie, Hopital Necker, Paris, France
Blood Purif 22:38-43. 2004..In my opinion, the calcimimetics will not replace currently used medications but will be a valuable supplement to presently available treatment options for this major complication in patients with renal failure... - Modulation and action of the calcium-sensing receptorTilman B Drueke
Inserm Unit 507 and Service de Néphrologie, Hopital Necker, Paris, France
Nephrol Dial Transplant 19:V20-26. 2004..These compounds have considerable potential for the treatment of primary and secondary hyperparathyroidism... - Treatment of secondary hyperparathyroidism of dialysis patients with calcimimetics as a valuable addition to established therapeutic meansTilman B Drueke
INSERM Unit 507, Service de Nephrologie, Hopital Necker, 161 rue de Sevres, 75743 Paris Cedex 15, France
Pediatr Nephrol 20:399-403. 2005..Since all available experience has been gathered in adult patients it is also necessary to test the efficacy and safety of the calcimimetics in children with CKD... 
Is parathyroid hormone measurement useful for the diagnosis of renal bone disease?T B Drueke
Institut National de la Santé et de la Recherche Medical INSERM Unité 845 and Service de Néphrologie, Hopital Necker, Assistance Publique Hopitaux de Paris, and Faculté de Médecine René Descartes Paris 5, Paris, France
Kidney Int 73:674-6. 2008..Although very high serum PTH levels generally allow the diagnosis of high bone turnover, slight elevations, normal, or low values cannot allow a reliable distinction between normal or low turnover...- Lanthanum carbonate as a first-line phosphate binder: the "cons"Tilman B Drueke
Service de Néphrologie and Inserm U 845, Necker Hospital, Paris, France
Semin Dial 20:329-32. 2007..Our experience with aluminum hydroxide suggests caution regarding the long-term use of another metal-based agent that displays enhanced absorption in the uremic state and progressive tissue accumulation... - Which vitamin D derivative to prescribe for renal patientsTilman B Drueke
Inserm Unit 507 and Service de Néphrologie, Hopital Necker, Paris, France
Curr Opin Nephrol Hypertens 14:343-9. 2005..Their possible advantages and their precise place in the treatment and prevention of secondary hyperparathyroidism remain a matter of debate... - Pathophysiological aspects of vascular calcification in chronic renal failureT B Drueke
Inserm U507 and Service de Néphrologie, Hopital Necker, Paris
Nefrologia 25:96-9. 2005..The recognition of the main factors involved will allow in the future a more appropriate prophylactic and therapeutic approach of this clinically important complication of chronic renal failure... - Progression of vascular calcification in uraemic patients: can it be stopped?Tilman B Drueke
Inserm U507 and Service de Néphrologie, Hopital Necker, Paris, France
Nephrol Dial Transplant 17:1365-8. 2002 - Role of secondary hyperparathyroidism in erythropoietin resistance of chronic renal failure patientsTilman B Drueke
Inserm Unit 507 and Division of Nephrology, Necker Hospital, Paris, France
Nephrol Dial Transplant 17:28-31. 2002..However, overall, the importance of hyperparathyroidism appears to be minor compared with other factors such as iron deficiency or inflammation... - Medical management of secondary hyperparathyroidism in uremiaT B Drueke
Institut National de la Santé et de la Recherche Médicale Unité 507 and Division of Nephrology, Necker Hospital, Paris, France
Am J Med Sci 317:383-9. 1999..Some of them already have entered the stage of clinical evaluation, and preliminary results are promising... - Genesis of atherosclerosis in uremic patientsT B Drueke
INSERM Unité 507 and Division of Nephrology, Necker Hospital, Paris, France
Miner Electrolyte Metab 25:251-7. 1999..Controlled long-term studies are required to reach valid conclusions on the implications of the numerous factors which theoretically may play a role in the atherosclerotic complications of chronic renal failure patients... - Aspects of cardiovascular burden in pre-dialysis patientsT B Drueke
Departement de Nephrologie, Hopital Necker, Paris, France
Nephron 85:9-14. 2000..It is well recognised that dialysis patients have a high burden of factors that predispose to CVD. What is less clear is the extent of this problem in the pre-dialysis patient. This is the subject of this review... - Normalization of hemoglobin level in patients with chronic kidney disease and anemiaTilman B Drueke
Inserm Unité 507 and Assistance Publique Hôpitaux de Paris, Necker Hospital, Division of Nephrology, Paris, France
N Engl J Med 355:2071-84. 2006..Whether correction of anemia in patients with stage 3 or 4 chronic kidney disease improves cardiovascular outcomes is not established... - Control of secondary hyperparathyroidism by vitamin D derivativesT B Drueke
Inserm Unit 705 and Division of Nephrology, Necker Hospital, Paris, France
Am J Kidney Dis 37:S58-61. 2001..The nephrology community is still waiting for the advent of nonhypercalcemic and nonhyperphosphatemic vitamin D analogs with PTH suppressive activity equal to the parent compound calcitriol or its immediate precursor, alfacalcidol... - Role of oxidized low-density lipoprotein in the atherosclerosis of uremiaT B Drueke
INSERM U507, Division of Nephrology, and Biochemistry Laboratory A, Necker Hospital, Paris, France
Kidney Int Suppl 78:S114-9. 2001..These oxidative changes of LDL protein moiety, if shown to occur to a significant extent in uremic patients in vivo, may represent an important alternative pathway in the pathogenesis of atheromatous lesions... - Genetic aspects of secondary hyperparathyroidism in uremiaT B Drueke
INSERM Unit 507, Necker Hospital, Paris, France
Am J Kidney Dis 38:S143-6. 2001.... - Uremia accelerates both atherosclerosis and arterial calcification in apolipoprotein E knockout miceZiad A Massy
INSERM Unit 507, Necker Hospital, 161, rue de Sèvres 75015 Paris, France
J Am Soc Nephrol 16:109-16. 2005..We anticipate that this experimental model will be useful to test treatment strategies aimed at decreasing the accelerated atherosclerosis and arterial calcification in uremia... - The calcimimetic R-568 retards uremia-enhanced vascular calcification and atherosclerosis in apolipoprotein E deficient (apoE-/-) miceOgnen Ivanovski
Inserm Unit 845, Necker Hospital, Paris Descartes University Paris V, Paris, France
Atherosclerosis 205:55-62. 2009.... - Cinacalcet treatment in dialysis patients with secondary hyperparathyroidism: effects and open issuesTilman B Drueke
Inserm Unit 845 and Nephrology, Necker Hospital, Paris, France
Ther Apher Dial 12:S2-12. 2008..Hopefully, in the future, this improvement will be shown to be associated with better patient outcomes for the treatment of fractures and cardiovascular morbidity and mortality... - Treatment of secondary hyperparathyroidism in CKD patients with cinacalcet and/or vitamin D derivativesTilman B Drueke
INSERM Unité 845 and Service de Néphrologie, Hopital Necker, Tour Lavoisier, Paris Cedex 15, France
Clin J Am Soc Nephrol 4:234-41. 2009..Future randomized controlled trial must answer whether calcimimetics impact on cardiovascular events or survival and whether in this respect there are differences between vitamin D sterols and calcimimetics... - Sevelamer prevents uremia-enhanced atherosclerosis progression in apolipoprotein E-deficient miceOlivier Phan
INSERM Unit 507, Necker Hospital, Paris, France
Circulation 112:2875-82. 2005.... - Absence of response to human parathyroid hormone in athymic mice grafted with human parathyroid adenoma, hyperplasia or parathyroid cells maintained in cultureB G Hory
Unité 90 de l INSERM and Département de Néphrologie, Hopital Necker, Paris, France
J Endocrinol Invest 23:273-9. 2000..We suggest that this strain of mice could be used for better understanding the relationship between cytokines and bone turnover... - Caspase-dependent apoptosis in THP-1 cells exposed to oxidized low-density lipoproteinsS Vicca
INSERM U507, Necker Hospital, Paris, France
Biochem Biophys Res Commun 273:948-54. 2000..Moreover, the resistance of differentiated THP-1 cells to oxLDL-induced apoptosis is compatible with the hypothesis that mature macrophages have prolonged survival and thereby enhance the atherogenic process... - Homocyst(e)ine, oxidative stress, and endothelium function in uremic patientsZ A Massy
Division of Nephrology, INSERM U507, and Biochemistry A and B Laboratories, Necker Hospital, Paris, France
Kidney Int Suppl 78:S243-5. 2001..These data must be confirmed in additional studies. Moreover, the relative importance of homocysteine-induced oxidant stress versus other potential mechanisms of endothelium dysfunction in these patients remains to be determined... - Animal models--what they can tell us about vascular calcification in CKDZiad A Massy
INSERM, ERI12, Amiens, France, and Amiens University Hospital, UPJV, Amiens, France
Semin Dial 20:110-2. 2007..In this review, we discuss how animal models could help us understand better the pathophysiology and management of calcifying cardiovascular complications associated with CKD... - Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administrationBernard Lacour
Laboratoire de Biochimie A, Hopital Necker, Paris, France
Kidney Int 67:1062-9. 2005..In the present study, we examined this issue in two different rat models of CRF... - The antioxidant N-acetylcysteine prevents accelerated atherosclerosis in uremic apolipoprotein E knockout miceOgnen Ivanovski
INSERM Unit 507, Necker Hospital, Paris, France
Kidney Int 67:2288-94. 2005..Here we examine a possible direct effect of NAC supplementation on uremia-enhanced atherosclerosis in apolipoprotein E-deficient (apoE(-/-)) mice... - Increased pasma S-nitrosothiol concentrations predict cardiovascular outcomes among patients with end-stage renal disease: a prospective studyZiad A Massy
INSERM U507, Necker Hospital, Paris, France
J Am Soc Nephrol 15:470-6. 2004..These findings support the hypothesis that impaired S-nitrosothiol bioavailability in uremia is an important factor for the excessive cardiovascular risk among HD patients... - Increased plasma S-nitrosothiol levels in chronic haemodialysis patientsZiad A Massy
INSERM U507, Necker Hospital, Paris, France
Nephrol Dial Transplant 18:153-7. 2003..The aim of our study was to determine the plasma levels of S-nitrosothiol and nitrotyrosine in chronic HD patients, and to evaluate potential factors influencing their levels... - Beta2-microglobulinTilman B Drueke
Inserm Unit 845, Necker Medical School, University Paris Descartes, Paris, France
Semin Dial 22:378-80. 2009..The prevalence and severity of beta2-M amyloidosis appear to have decreased in the last 20 years, although its occurrence may simply be delayed... - Effects of calcimimetic on vascular calcification and atherosclerosis in uremic miceNobuhiko Joki
Inserm Unit 845, Necker Hospital, University Paris 5, Paris, France
Bone 45:S30-4. 2009..The present review is therefore devoted to the effects of calcimimetics on uremia-induced vascular disease... - Effect of oral calcium carbonate on aortic calcification in apolipoprotein E-deficient (apoE-/-) mice with chronic renal failureOlivier Phan
INSERM, Unit 845, Necker Hospital, Universite Paris V, Paris, France
Nephrol Dial Transplant 23:82-90. 2008..The aim of this study was to reexamine the role of calcium carbonate in vascular calcification and to analyse its effect on aortic calcification-related gene expression in chronic renal failure (CRF)... - Variation in serum and plasma PTH levels in second-generation assays in hemodialysis patients: a cross-sectional studyDominique Joly
Service de Nephrologie, Laboratoire d Explorations Fonctionnelles and Inserm Unit 845, Hopital Necker Enfants Malades, Assistance Publique Hopitaux de Paris, Universite Paris Descartes, Paris, France
Am J Kidney Dis 51:987-95. 2008..In this cross-sectional study, we aim to determine the usefulness of standardizing blood handling for optimal interpretation of PTH in patients with chronic kidney disease... - Tissue accumulation of lanthanum as compared to aluminum in rats with chronic renal failure--possible harmful effects after long-term exposureIgor G Nikolov
lnserm Unit 845, University Paris V, Paris, France
Nephron Exp Nephrol 115:e112-21. 2010..Lanthanum (La) carbonate is a new treatment for hyperphosphatemia. We tested the effects of oral La carbonate and aluminum hydroxide, respectively, on tissue accumulation and liver function in rats with chronic renal failure (CRF)... - Epithelial abnormalities in intestine and kidney of the spontaneously hypertensive ratT B Drueke
INSERM Unité 90, Hopital Necker, Paris, France
Am J Hypertens 3:195S-201S. 1990..abstract truncated at 250 words).. - Effect of simvastatin in apolipoprotein E deficient mice with surgically induced chronic renal failureOgnen Ivanovski
Institut National en Santé et Recherche Médicale Unit 845, Paris, France
J Urol 179:1631-6. 2008.... - Calcium balance in haemodialysis--do not lower the dialysate calcium concentration too much (con part)Tilman B Drueke
INSERM U845, Hopital Necker, Universite Paris V, Paris, France
Nephrol Dial Transplant 24:2990-3. 2009..We would like to take issue with this statement and warn against the indiscriminate use of a low calcium dialysate in all patients receiving haemodialysis therapy... - Optimal dialysate calcium and vascular calcificationNobuhiko Joki
Nephrol Dial Transplant 22:3354; author reply 3354-5. 2007 - Factors involved in vascular calcification and atherosclerosis in maintenance haemodialysis patientsAndrzej Kraśniak
Department of Nephrology, Jagiellonian University, 31 501 Krakow, ul Kopernika 15c, Poland
Nephrol Dial Transplant 22:515-21. 2007..The aim of the present study was to evaluate the degree of atherosclerosis and vascular calcifications in chronic haemodialysis patients using non-invasive imaging methods, and to identify potentially involved factors... - A uniform clinical trial registration policy for journals of kidney diseases, dialysis and transplantationWilliam G Couser
Journal of the American Society of Nephrology
Am J Transplant 5:643. 2005